20.1
Pulmonale hypertensie: classificatie en pathogenese
Pulmonale hypertensie (PH) is een ernstige gezondheidstoestand waarbij de gemiddelde pulmonale arteriële druk stijgt tot 25 mmHg of meer, zelfs wannee…
Pulmonary hypertension, or PH, denotes the resting mean pulmonary arterial pressure of 25 mm Hg or higher.
Pulmonary hypertension can be classified into PH due to left heart disease, lung diseases or hypoxia, chronic thromboembolic PH, PH with unclear multifactorial mechanisms, and pulmonary arterial hypertension or PAH.
PAH is a rare, fatal condition characterized by vascular changes in small arteries and arterioles, leading to elevated pulmonary arterial pressure and vascular resistance.
The key mechanisms in PAH include pulmonary vascular remodeling, sustained pulmonary vasoconstriction, in situ thrombosis, and stiffening of the pulmonary vascular wall.
Decreased vasoactive mediators like prostacyclin and increased vasoconstrictors like ET-1 contribute to vasoconstriction.
Symptoms of PH encompass dyspnea, fatigue, chest pain, and syncope.
Potential therapeutic options for PH include cGMP signaling stimulators, nitric oxide therapies, membrane receptor antagonists and agonists, and ion channel blockers.
View the full transcript and gain access to JoVE Core videos
Q1: What is the diagnostic threshold for pulmonary hypertension?
Pulmonary hypertension is diagnosed when the resting mean pulmonary arterial pressure reaches 25 mm Hg or higher. This elevated pressure in the blood vessels transporting blood from the heart to the lungs can cause significant symptoms and lead to right heart failure. The condition affects overall quality of life and requires prompt medical evaluation.
Q2: How is pulmonary arterial hypertension different from other types of pulmonary hypertension?
Pulmonary arterial hypertension (PAH) is a rare, fatal form characterized by vascular changes in small arteries and arterioles, causing elevated pulmonary arterial pressure and vascular resistance. Unlike other PH types linked to left heart disease, lung disease, or blood clots, PAH involves distinct mechanisms including pulmonary vascular remodeling, sustained vasoconstriction, in situ thrombosis, and vascular wall stiffening.
Q3: What causes pulmonary vasoconstriction in pulmonary arterial hypertension?
Pulmonary vasoconstriction in PAH results from imbalanced vasoactive mediators. Decreased vasodilators like nitric oxide and prostacyclin reduce vessel widening, while increased vasoconstrictors like endothelin-1 (ET-1) promote narrowing and smooth muscle cell proliferation. This mediator imbalance drives sustained constriction and worsens vascular resistance.
Q4: What are the main symptoms of pulmonary hypertension?
Pulmonary hypertension symptoms include dyspnea (shortness of breath), fatigue, chest pain, and syncope (fainting). These symptoms typically worsen over time, progressively limiting patients' ability to perform routine activities. Early recognition of these signs is important for timely diagnosis and intervention.
Q5: What therapeutic mechanisms are used to treat pulmonary arterial hypertension?
Treatment for pulmonary arterial hypertension employs multiple mechanisms: cGMP signaling stimulators enhance vasodilation, nitric oxide therapies promote vessel widening, membrane receptor antagonists and agonists modulate vasoactive pathways, and ion channel blockers reduce vascular resistance. Treatment choice depends on PAH severity and patient health status.
Q6: How do the five classifications of pulmonary hypertension differ?
The five PH classifications are: PH due to left heart disease, PH from lung diseases or hypoxia, chronic thromboembolic PH (caused by blood clots), PH with unclear multifactorial mechanisms, and pulmonary arterial hypertension (PAH). Each classification relates to different underlying causes, treatment approaches, and prognoses, guiding clinical management decisions.
Q7: What structural changes occur in the pulmonary vasculature during pulmonary arterial hypertension?
PAH involves multiple vascular structural changes: pulmonary vascular remodeling alters vessel architecture, sustained vasoconstriction narrows blood vessels, in situ thrombosis causes clotting within vessels, and vascular wall stiffening reduces elasticity. These combined changes increase pulmonary arterial pressure and vascular resistance, progressively impairing lung blood flow.